It is therefore possible that clusterin could be used in conjunction with cognitive testing with tests such as the ECAS, to improve the sensitivity of the detection of TDP‐43 pathology in nonmotor brain regions, in ALS patients and improve (i) prognostication regarding risk of developing cognitive impairment and (ii) stratification for clinical trials. Here, TARDBP is linked to Cognitive impairment.